-1.55%
-7.38%
30.07%
19.60%
15.12%
79.64%
20.73%
AI Spotlight on MDXG
Company Description
MiMedx Group, Inc.develops and distributes placental tissue allografts for various sectors of healthcare.It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form.The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare.
It also sells allografts for dental applications on an original equipment manufacturer basis.The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States.MiMedx Group, Inc.
is headquartered in Marietta, Georgia.
Market Data
| Last Price | 8.91 |
| Change Percentage | -1.55% |
| Open | 9.1 |
| Previous Close | 9.05 |
| Market Cap ( Millions) | 1309 |
| Volume | 324789 |
| Year High | 10.14 |
| Year Low | 5.47 |
| M A 50 | 9.19 |
| M A 200 | 7.32 |
Financial Ratios
| FCF Yield | 4.44% |
| Dividend Yield | 0.00% |
| ROE | 60.34% |
| Debt / Equity | 10.51% |
| Net Debt / EBIDTA | -105.81% |
| Price To Book | 7.23 |
| Price Earnings Ratio | 13.41 |
| Price To FCF | 22.53 |
| Price To sales | 3.82 |
| EV / EBITDA | 18.79 |
News
- Dec -02 - Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
- Dec -02 - Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
- Nov -20 - How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%
- Nov -15 - MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why
- Nov -14 - MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
- Nov -04 - Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
- Oct -31 - MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
- Oct -30 - MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
- Oct -30 - MIMEDX Announces Third Quarter 2024 Operating and Financial Results
- Oct -14 - MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
- Oct -08 - MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
- Oct -01 - MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
- Sep -11 - EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"
- Sep -04 - THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
- Aug -26 - DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
- Aug -01 - MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript
- Jul -31 - MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
- Jul -31 - MIMEDX Announces Second Quarter 2024 Operating and Financial Results
- Jul -22 - MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
- Jul -01 - 7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Hospital
Expected Growth : 10.2 %
What the company do ?
MiMedx Group, Inc.'s Hospital segment provides amniotic tissue-based products for wound care and surgical applications to hospitals and other healthcare facilities.
Why we expect these perspectives ?
Growing demand for advanced wound care and surgical applications, increasing adoption of amniotic tissue-based products, and expanding hospital and healthcare facility networks drive growth in MiMedx's Hospital segment.
Segment n°2 -> Private Office
Expected Growth : 12.4 %
What the company do ?
The Private Office is a physician-led network of practices offering regenerative medicine solutions, providing access to MiMedx's advanced wound care products.
Why we expect these perspectives ?
Growing demand for regenerative medicine solutions, increasing adoption of advanced wound care products, and expanding physician network are driving growth in the private office segment.
Segment n°3 -> Other
Expected Growth : 10.5 %
What the company do ?
The 'Other' segment from MiMedx Group, Inc. includes sales from private label and original equipment manufacturer (OEM) products, as well as royalties and license fees.
Why we expect these perspectives ?
The 'Other' segment's growth is driven by increasing demand for private label and OEM products, as well as rising royalties and license fees from partnerships and collaborations.
Mimedx Group, Inc. Products
| Product Range | What is it ? |
|---|---|
| EpiFix | A dehydrated human amnion/chorion membrane allograft used for wound care and surgical applications |
| EpiFix Micronized | A micronized version of EpiFix, used for injection into tissues to promote healing and tissue repair |
| AmnioFix | A dehydrated human amnion/chorion membrane allograft used for orthopedic and sports medicine applications |
| AmnioFix Inject | A micronized version of AmnioFix, used for injection into joints and tissues to promote healing and tissue repair |
| EpiCord | A dehydrated human umbilical cord allograft used for wound care and surgical applications |
MiMedx Group, Inc.'s Porter Forces
Threat Of Substitutes
MiMedx Group, Inc. operates in the biopharmaceutical industry, where substitutes are limited. However, the company's products may face competition from alternative treatments or therapies, which could impact its market share.
Bargaining Power Of Customers
MiMedx Group, Inc.'s customers are primarily healthcare providers and patients, who have limited bargaining power due to the specialized nature of the company's products.
Bargaining Power Of Suppliers
MiMedx Group, Inc. relies on a limited number of suppliers for raw materials and services, which could lead to moderate bargaining power. However, the company's diversified supplier base and long-term contracts mitigate this risk.
Threat Of New Entrants
The biopharmaceutical industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and intellectual property protections, making it difficult for new entrants to compete with MiMedx Group, Inc.
Intensity Of Rivalry
The biopharmaceutical industry is highly competitive, with several established players competing for market share. MiMedx Group, Inc. faces intense competition from companies with similar product offerings and strong research and development capabilities.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 25.81% |
| Debt Cost | 6.10% |
| Equity Weight | 74.19% |
| Equity Cost | 11.10% |
| WACC | 9.81% |
| Leverage | 34.79% |
MiMedx Group, Inc. : Quality Control
MiMedx Group, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CTMX | CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The … |
| AKBA | Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral … |
| LQDA | Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of … |
| ARMP | Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's … |
| URGN | UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Akebia Therapeutics
A-Score
1-Year Total Return ->
🥈
MiMedx
A-Score
1-Year Total Return ->
🥉
CytomX Therapeutics
A-Score
1-Year Total Return ->
4
Armata Pharmaceuticals
A-Score
1-Year Total Return ->
5
UroGen Pharma
A-Score
1-Year Total Return ->
6
